Pharma and Biotech
Latest | F'cast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | -39.3% | n/a |
ROCE | n/a |
Latest | F'cast | |
---|---|---|
P/E | n/a | 140.0 |
PEG | n/a | n/a |
Pr/Revenue | 2.3 | 1.4 |
Pr/Book | 0.9 |
Latest | F'cast | |
---|---|---|
Revenue | -13.1% | 58.5% |
PBT | n/a | n/a |
EPS | n/a | n/a |
DPS | n/a | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Sep-20 | 105.57 | (22.57) | (3.80)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-21 | 125.06 | (9.18) | (1.93)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-22 | 157.71 | (21.38) | (4.34)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-23 | 103.96 | (24.70) | (3.21)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-24 | 90.36 | (45.92) | (5.99)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Sep-25 | 143.20 | n/a | 0.20p | 143.0 | n/a | n/a | n/a | 0.0% |
30-Sep-26 | 149.50 | n/a | 0.40p | 71.5 | 0.7 | +100% | n/a | 0.0% |
Copyright © 2025 FactSet Research Systems Inc. All rights reserved.
Publication of Annual Report | 07-Jan-2025 | 07:00 | RNS |
Total Voting Rights | 31-Dec-2024 | 07:00 | RNS |
Result of General Meeting | 16-Dec-2024 | 13:00 | RNS |
No deals were found in the last 28 days.
Currency | UK Pounds |
Share Price | 28.60p |
Change Today | 1.10p |
% Change | 4.00 % |
52 Week High | 48.00 |
52 Week Low | 27.10 |
Volume | 1,368,847 |
Shares Issued | 740.34m |
Market Cap | £211.74m |
Beta | 0.03 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 1 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 1 |
No dividends found |
Time | Volume / Share Price |
16:35 | 85 @ 28.60p |
16:35 | 51 @ 28.60p |
16:35 | 34 @ 28.60p |
16:08 | 8,000 @ 28.70p |
15:35 | 2,500 @ 28.70p |
CFO | Septima Maguire |
CEO | Trond Williksen |
Chair | Tripp Lane |
You are here: research